Zhongsheng Beikong Biotechnology (08247) received Chen Peng, the main shareholder, an increase of about 4.32 million shares of the company's domestic shares

Zhitong Finance App News, Zhongsheng Beikong Biotechnology (08247) announced that from June 15 to July 14, 2026, the company's chairman, president, executive director and main shareholder Mr. Chen Peng, through Jingning Guoke Kangyi Enterprise Management Center (limited partnership) and Guoke Health Institute (Hefei) partnership (limited partnership), at a total cost of about RMB 10.53 million (purchase price is RMB 2.40 to RMB 2.50 per share), and jointly acquired about 4.32 million shares of the company on the market. Of the total number of shares issued 2.97%

Following the above increase in holdings, on the date of this announcement, Mr. Chen Peng held 156.30,500 domestic shares through (i) Guoke Kangyi and the National Science and Health Institute; and (ii) HK Zhixin Investment Co., Limited held approximately 27.2561 million H shares of the company, which together accounted for about 29.64% of the total number of issued shares (of which domestic shares and H shares account for about 19.44% and 42.40% of their respective issued share categories).